News for Retractable Technologies, Inc. (RVP)

Retractable Technologies, Inc. (RVP) reports total net sales of $8.3 million for Q1 2025, up from $7.6 million in Q1 2024. The company experienced an op

Retractable Technologies, Inc. (RVP) has announced a 7% reduction in its workforce, a strategic move expected to save the company approximately $1.6 million ann

Retractable Technologies, Inc. Withdraws Complaint in United States Court of International Trade

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

Retractable Technologies CEO Thomas Shaw acquires $5,422 in stock

Retractable Technologies CEO Thomas J. Shaw acquires $6,876 in stock

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

Retractable Technologies CEO buys $58.9k in company stock

Retractable Technologies CEO buys $25,626 in company stock

RVP stock touches 52-week low at $0.85 amid market challenges

Retractable technologies CEO buys shares worth $403

Retractable technologies CEO buys $7.8k in company stock

Loading... Loading... The Dow Jones index closed lower by over 50 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or co...

Loading... Loading... The Dow Jones index closed slightly higher on Friday. When insiders purchase or sell shares, it indicates their confidence or concern aro...

The Dow Jones index closed higher by around 60 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.40 A.M. ET)..

Today's Daily Dose brings you news about FDA approval of Adamas' GOCOVRI for an expanded indication, positive results from Arcutis' plaque psoriasis trial, Concert Pharma's disappointing data from schizophrenia trial, and the progress in Clover's phase I adjuvanted trial of COVID-19 S-Trimer vaccine candidates, to name a few.